SAMANTHA BELLINGER: Open Payments
NPI 1275902900 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$13,619 in 264 payments from 23 companies in 2025. Trend: 2023 $8,994 · 2024 $10,284 · 2025 $13,619
Food & beverage: $6,118Speaker / faculty: $4,988Consulting: $2,088Travel & lodging: $424
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 24 | $6,191 |
| Regeneron Healthcare Solutions, Inc. | 24 | $3,038 |
| AstraZeneca Pharmaceuticals LP | 37 | $1,003 |
| Insmed, Inc. | 33 | $698 |
| GlaxoSmithKline, LLC. | 30 | $428 |
| United Therapeutics Corporation | 8 | $321 |
| Pulmonx Corporation | 14 | $320 |
| Amgen Inc. | 17 | $265 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $237 |
| Verona Pharma, Inc. | 19 | $226 |
Products named: DUPIXENT, Arikayce, FASENRA, TEZSPIRE, CHARTIS CATHETER, NUCALA, Ohtuvayre, Tyvaso.
Industry payments across OK — which companies pay providers there.
